SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Augmedix, Inc. – ‘8-K’ for 4/9/24

On:  Monday, 4/15/24, at 4:05pm ET   ·   For:  4/9/24   ·   Accession #:  1213900-24-32951   ·   File #:  1-40890

Previous ‘8-K’:  ‘8-K’ on / for 3/18/24   ·   Next & Latest:  ‘8-K’ on 4/18/24 for 4/15/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/15/24  Augmedix, Inc.                    8-K:1,9     4/09/24   11:206K                                   EdgarAgents LLC/FA

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     27K 
 2: EX-10.1     Seventh Omnibus Amendment, Entered Into on April    HTML     16K 
                9, 2024, by and Among Augmedix Operating Corp.                   
                F/K/A Augmedix, Inc., Dignity Health, Dignity                    
                Health Medical Foundation, and Pacific Central                   
                Coast Health Centers.                                            
 6: R1          Cover                                               HTML     49K 
 8: XML         IDEA XML File -- Filing Summary                      XML     12K 
11: XML         XBRL Instance -- ea0203920-8k_augmedix_htm           XML     17K 
 7: EXCEL       IDEA Workbook of Financial Report Info              XLSX      8K 
 4: EX-101.LAB  XBRL Labels -- augx-20240409_lab                     XML     96K 
 5: EX-101.PRE  XBRL Presentations -- augx-20240409_pre              XML     64K 
 3: EX-101.SCH  XBRL Schema -- augx-20240409                         XSD     12K 
 9: JSON        XBRL Instance as JSON Data -- MetaLinks               25±    34K 
10: ZIP         XBRL Zipped Folder -- 0001213900-24-032951-xbrl      Zip     19K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX: 
 i false  i 0001769804 0001769804 2024-04-09 2024-04-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM  i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported):  i April 9, 2024

 i AUGMEDIX, INC.

(Exact name of registrant as specified in its charter)

 

 i Delaware    i 001-40890    i 83-3299164

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

 i 111 Sutter Street,  i Suite 1300,  i San Francisco,  i California  i 94104

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code:  i (888)  i 669-4885

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 i  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 i  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 i  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 i  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
 i Common Stock, $0.0001 par value per share    i AUGX   The  i Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  i 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  i 

 

 

Item 1.01. Entry into a Material Definitive Agreement

On April 9, 2024 (the “Effective Date”), Augmedix Operating Corp., a Delaware corporation (f/k/a Augmedix, Inc., the “Company”), and subsidiary of Augmedix, Inc., entered into a Seventh Omnibus Amendment (the “Amendment”) with Dignity Health (“DH”), Dignity Health Medical Foundation (“DHMF”), and Pacific Central Coast Health Centers (“PHC”) to amend the statements of work (the “SOWs”) previously entered into between the Company and each of DH, DHMF and PHC pursuant to a Services Agreement, dated September 1, 2015, by and between the Company and CommonSpirit Health (f/k/a Catholic Health Initiative) (“CommonSpirit”), as successor-in-interest to Dignity Health (the “Agreement”). The Amendment extends the term of the SOWs through June 30, 2024 and memorializes the intent of the Company and CommonSpirit to negotiate in good faith a new enterprise-wide agreement.

A copy of the Amendment is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

 

 Exhibit 
No.

  Description
10.1   Seventh Omnibus Amendment, entered into on April 9, 2024, by and among Augmedix Operating Corp. f/k/a Augmedix, Inc., Dignity Health, Dignity Health Medical Foundation, and Pacific Central Coast Health Centers.
104   Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

AUGMEDIX, INC.
     
Dated: April 15, 2024 By: /s/ Paul Ginocchio
    Paul Ginocchio
    Chief Financial Officer

 

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
6/30/24
Filed on:4/15/24
For Period end:4/9/244,  4/A
9/1/15
 List all Filings 
Top
Filing Submission 0001213900-24-032951   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Apr. 30, 4:45:38.1pm ET